microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Authors
Keywords
-
Journal
JCI Insight
Volume 5, Issue 23, Pages -
Publisher
American Society for Clinical Investigation
Online
2020-10-30
DOI
10.1172/jci.insight.143812
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Micro RNA ‐483 amelioration of experimental pulmonary hypertension
- (2020) Jin Zhang et al. EMBO Molecular Medicine
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Emerging Issues in AAV-Mediated In Vivo Gene Therapy
- (2018) Pasqualina Colella et al. Molecular Therapy-Methods & Clinical Development
- Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes.
- (2018) Leslie R Sedgeman et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
- (2018) Cory D. Sago et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- sgRNA Scorer 2.0: A Species-Independent Model To Predict CRISPR/Cas9 Activity
- (2017) Raj Chari et al. ACS Synthetic Biology
- Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
- (2017) Parisa Naeli et al. Frontiers in Genetics
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal TransitionNovelty and Significance
- (2016) Ming He et al. CIRCULATION RESEARCH
- ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
- (2016) Philip L.S.M. Gordts et al. JOURNAL OF CLINICAL INVESTIGATION
- MicroRNA-27 Prevents Atherosclerosis by Suppressing Lipoprotein Lipase-Induced Lipid Accumulation and Inflammatory Response in Apolipoprotein E Knockout Mice
- (2016) Wei Xie et al. PLoS One
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of Atherosclerosis in Mice and Hamsters Without Germline Genetic Engineering
- (2014) Martin Mæng Bjørklund et al. CIRCULATION RESEARCH
- Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice
- (2014) Fuyuan Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin–angiotensin system
- (2014) Jacqueline R. Kemp et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- An SREBP-Responsive microRNA Operon Contributes to a Regulatory Loop for Intracellular Lipid Homeostasis
- (2013) Tae-Il Jeon et al. Cell Metabolism
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP
- (2010) Markus Hafner et al. CELL
- MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
- (2010) K. J. Rayner et al. SCIENCE
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started